Cannabis and the increased incidence and persistence of psychosis

BMJ

Volumn 342, Issue 7796, 2011, Pages 511-512

  Hall, Wayne ^a   Degenhardt, Louisa ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; NEUROLEPTIC AGENT; TETRAHYDROCANNABINOL;

CANNABIS SMOKING; CAUSAL ATTRIBUTION; CORRELATIONAL STUDY; DISEASE PREDISPOSITION; DRUG SENSITIVITY; EDITORIAL; EVIDENCE BASED MEDICINE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; INCIDENCE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA;

HUMANS; INCIDENCE; MARIJUANA ABUSE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 79952272182     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d719     Document Type: Editorial

References (12)

1. Moore T, Zammit S, Lingford-Hughes A, Barnes T, Jones P, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28. (Pubitemid 47094993)
2. Degenhardt L, Hall WD. Is cannabis a contributory cause of psychosis? Can J Psychiatry 2006;51:556-65.
3. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004;363:1579-88. (Pubitemid 38625660)
4. Kuepper R, Henquet C, van Os J, Lieb R, Wittchen H-U, Höfler M. Continued cannabis use and incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011;342:d738.
5. Fergusson D, Horwood L, Ridder E. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005;100:354-66. (Pubitemid 40363442)
6. Zammit S, Moore T, Lingford-Hughes A, Barnes T, Jones P, Burke M, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008;193:357.
7. D'Souza D, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29:1558-72. (Pubitemid 38982249)
8. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005;57:594-608. (Pubitemid 40409699)
9. Hall W, Degenhardt L. What are the policy implications of the evidence on cannabis and psychosis? Can J Psychiatry 2006;51:566-74.
10. Hall W, Degenhardt L. The adverse health and psychological effects of non-medical cannabis use. Lancet 2009;374:1383-91.
11. Hickman M, Vickerman P, Macleod J, Lewis G, Zammit S, Kirkbride J, et al. If cannabis caused schizophrenia - how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction 2009;104:1856-61.
12. Room R, Fischer B, Hall W, Lenton S, Reuter P. Cannabis policy: moving beyond stalemate. Oxford University Press, 2010.